Disease transformation monitoring in polycythemia vera — the clinical surveillance for progression to post-polycythemia vera myelofibrosis (PPV-MF) or blast phase (acute leukemia) — which occurs in fifteen to twenty percent and five to fifteen percent of PV patients respectively at fifteen to twenty years — requiring systematic long-term follow-up strategies and the...

The Polycythemia Vera Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several factors, including the rising prevalence of polycythemia vera (PV), advancements in treatment options, and an increasing awareness of the disease among healthcare professionals and patients. The market...